Fresenius Kabi Oncology Ltd


BSE: 532545 | NSE: FKONCO | ISIN: INE575G01010 
Market Cap: [Rs.Cr.] 1,962 | Face Value: [Rs.] 1
Industry: Pharmaceuticals - Multinational

 Discuss this stock

Profit & Loss

(Rs. in Crores)
ParticularsMar-12Mar-11Mar-10Mar-09Mar-08Mar-07
INCOME :      
Sales Turnover 540.05426.13422.32268.24250.26312.70
Excise Duty15.7313.3611.0411.159.4213.66
Net Sales524.32412.77411.28257.09240.84299.04
Other Income 47.3831.2916.3333.39179.656.27
Stock Adjustments -6.02-7.0530.1226.356.373.85
Total Income565.68437.01457.73316.83426.86309.16
EXPENDITURE :      
Raw Materials 208.90128.29148.9497.5569.0592.08
Power & Fuel Cost17.7712.9311.2310.445.364.55
Employee Cost 60.9856.1145.9969.9228.3738.97
Other Manufacturing Expenses 38.3726.8430.2429.9718.1215.05
Selling and Administration Expenses 107.7291.2382.6383.6182.82102.51
Miscellaneous Expenses 18.6116.6620.6966.4817.5914.21
Less: Pre-operative Expenses Capitalised0.000.000.000.000.000.00
Total Expenditure452.35332.06339.72357.97221.31267.37
Operating Profit113.33104.95118.01-41.14205.5541.79
Interest 17.6618.0319.4021.977.866.74
Gross Profit95.6786.9298.61-63.11197.6935.05
Depreciation23.9716.9212.5111.815.425.14
Profit Before Tax71.7070.0086.10-74.92192.2729.91
Tax14.8114.0012.801.1242.563.25
Fringe Benefit tax0.000.000.000.000.650.96
Deferred Tax5.946.76-6.931.66-0.280.45
Reported Net Profit50.9549.2480.23-77.70149.3425.25
Extraordinary Items 31.341.6712.792.840.020.04
Adjusted Net Profit19.6147.5767.44-80.54149.3225.21
Adjst. below Net Profit 0.000.000.000.000.000.00
P & L Balance brought forward263.15213.91133.68211.3865.0442.79
Statutory Appropriations 0.000.000.000.000.000.00
Appropriations 250.000.000.000.003.003.00
P & L Balance carried down64.10263.15213.91133.68211.3865.04
Dividend0.000.000.000.000.000.00
Preference Dividend0.000.000.000.000.000.00
Equity Dividend %0.000.000.000.000.000.00
Earnings Per Share-Unit Curr3.223.115.070.009.531.61
Earnings Per Share(Adj)-Unit Curr3.223.115.070.009.531.61
Book Value-Unit Curr37.4634.2231.1126.0331.8521.37

Peer Comparison

Company Market Cap
(Rs. in Cr.)
P/E (TTM)
(x)
P/BV (TTM)
(x)
EV/EBIDTA
(x)
ROE
(%)
ROCE
(%)
D/E
(x)
Glaxosmit Pharma 20,569.82 31.08 10.23 18.86 34.3 45.2 0.00
Sanofi India 5,670.68 31.35 4.75 13.73 15.4 22.5 0.00
Pfizer 3,232.12 15.69 1.89 9.41 15.0 22.1 0.00
Abbott India 2,983.93 17.97 4.61 12.08 24.3 34.8 0.00
Fres.Kabi Onco. 1,962.47 22.97 2.92 22.38 3.5 5.4 0.42
Astrazeneca Phar 1,841.38 0.00 18.46 140.28 10.7 15.2 0.03
Wyeth 1,768.30 13.60 3.08 7.61 33.4 45.1 0.01
Novartis India 1,602.47 13.38 1.78 10.43 20.0 28.8 0.00
Merck 1,070.87 13.39 2.21 7.04 17.5 25.5 0.00
Fulford (India) 234.00 0.00 1.62 0.00 -3.4 -4.7 0.00
Organon (India) 159.14 0.00 0.98 0.00 15.3 22.8 0.00

Futures & Options Quote

 
Expiry Date
NA
Instrument: NA
Expiry Date: NA
Strike Price: NA
Open Price: NA
Average Price: NA
No. of Contracts Traded: NA
Open Interest: NA
Underlying: NA
Option Type: NA
Market Lot: NA
Previous Close: NA
Day’s High | Low: NA | NA
Turnover (Cr.): NA
Open Int. Change: NA | NA
View detailed F& O quotes >>

Key Information

Key Executives:

Rakesh Bhargava , Chairman  

Dilip G Shah , Director  

Gerrit Steen , Director  

Michael Schonhofen , Director  


Company Head Office / Quarters:
B-310 Som Datt Chambers-I,
Bhikaji Cama Place,
New Delhi,
New Delhi-110066
Phone : 91-11-26105570
Fax : 91-11-26195965
E-mail : complianceofficer.india@fresenius-kabi.com
Web : http://www.fresenius-kabi-oncology.com
Registrars:
MCS Ltd
F-65 1st Floor
Okhla Industrial Are
Phase-I
New Delhi-110020

Fund Holding


Calendar

Jun-2013
M T W T F S S
17 18 19 20 21 22 23
IPO
listNo IPO today
Economic Events
list Foreign Buying Japan Bonds (Yen)
list Foreign Buying Japan Stocks (Yen)
Results
list Coromandel Inter